Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
J Leukoc Biol
; 94(6): 1201-6, 2013 Dec.
Article
en En
| MEDLINE
| ID: mdl-23695306
ABSTRACT
NSCLC remains one of the most challenging malignancies to treat. Despite the introduction of innovative therapies over the last decade, the 5-year survival of NSCLC is still <20%. Clearly, novel, therapeutic approaches are required. Targeting the immune system to derive meaningful clinical benefit has proved successful in various malignancies in recent years. As a result, there is renewed focus on the use of immunotherapy in lung cancer. In this review, we provide an overview of current immune-modulatory approaches in the treatment of NSCLC.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inmunoterapia
/
Neoplasias Pulmonares
Límite:
Humans
Idioma:
En
Revista:
J Leukoc Biol
Año:
2013
Tipo del documento:
Article
País de afiliación:
Reino Unido